1. Labcorp executives will speak at Morgan Stanley conference on Sept. 9. 2. The company leads in lab services, aiding drug approvals significantly. 3. Labcorp performs over 700 million tests annually worldwide.
The upcoming conference may generate interest but lacks immediate catalysts for stock movement. Prior conference appearances have yielded mixed results in stock performance.
While the conference is notable, it primarily serves as a platform for communication rather than indicating direct financial changes.
Market expectations may shift temporarily around the event but will stabilize post-conference. Historical patterns show short-term fluctuations surrounding significant healthcare conferences.
BURLINGTON, N.C., Aug. 27, 2025 /PRNewswire/ -- Labcorp (NYSE:LH), a global leader of innovative and comprehensive laboratory services, announced today that members of the executive management team will participate in a fireside chat at the Morgan Stanley 23rd Annual Global Healthcare Conference on Tuesday, Sept. 9, at 7:45 am ET.
A live audio webcast of the fireside chat will be available via the Company Investor Relations website at ir.Labcorp.com and archived for replay.
About Labcorp
Labcorp (NYSE:LH) is a global leader of innovative and comprehensive laboratory services that helps doctors, hospitals, pharmaceutical companies, researchers and patients make clear and confident decisions. We provide insights and advance science to improve health and improve lives through our unparalleled diagnostics and drug development laboratory capabilities. The company's nearly 70,000 employees serve clients in approximately 100 countries, provided support for more than 75% of the new drugs and therapeutic products approved in 2024 by the FDA, and perform more than 700 million tests annually for patients around the world. Learn more about us at www.labcorp.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/labcorp-to-speak-at-the-morgan-stanley-23rd-annual-global-healthcare-conference-302540374.html
SOURCE Labcorp Holdings Inc